Open access
Open access
Powered by Google Translator Translator

Vaccines

Study finds no increased risk of rare neurological events after covid vaccination.

18 Mar, 2022 | 09:31h | UTC

News Release: Study finds no increased risk of rare neurological events after covid vaccination – BMJ Newsroom

Original Study: Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis – The BMJ

Editorial: The neurological safety of covid-19 vaccines

 


Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

17 Mar, 2022 | 09:12h | UTC

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron – New England Journal of Medicine

Related: [Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

 


Effectiveness of the Sputnik V, AstraZeneca, and Sinopharm vaccines for the risk of infection and death due to COVID-19 in people older than 60 years in Argentina.

17 Mar, 2022 | 09:10h | UTC

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study – The Lancet

Commentary: Evaluating COVID-19 vaccines in the real world – The Lancet

 


Trends in HPV–associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017.

17 Mar, 2022 | 08:16h | UTC

Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017 – JAMA Network Open

Author Interview: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations

Related:

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

 


[Preprint] High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron.

15 Mar, 2022 | 09:59h | UTC

High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron – medRxiv

 

Commentary on Twitter

 


Another study suggests that a third vaccine dose is necessary to protect populations against the omicron variant.

11 Mar, 2022 | 10:14h | UTC

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study – The BMJ

News Release: Third vaccine dose critical for protecting populations against omicron variant – BMJ Newsroom

 

Commentary on Twitter

 


WHO says COVID boosters needed, reversing previous call.

9 Mar, 2022 | 09:49h | UTC

WHO says COVID boosters needed, reversing previous call – Associated Press

 

Commentary on Twitter

 


[News release – not published yet] New Sanofi and GSK vaccine demonstrates strong protection against severe Covid-19 in clinical trials.

8 Mar, 2022 | 08:53h | UTC

Commentary: New vaccine demonstrates strong protection against severe Covid-19 in clinical trials – CNN

News Release: Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

 


M-A: Efficacy of covid-19 vaccines in immunocompromised patients.

4 Mar, 2022 | 10:01h | UTC

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

News Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

 

Commentary on Twitter

 


Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

3 Mar, 2022 | 08:43h | UTC

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong – JAMA Pediatrics

Commentary: Study: Dosing change could reduce COVID-19 vaccine heart side effect in teens – UPI

Related:

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 


[Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.

1 Mar, 2022 | 08:54h | UTC

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant – medRxiv

Commentaries:

Pfizer Covid vaccine is less effective in kids 5 to 11, study finds – STAT

Pfizer Covid-19 vaccine effectiveness fell quickly for kids during Omicron surge but still offered some protection against severe disease – CNN

More mask mandates fall as poor COVID vaccine protection noted in young kids – CIDRAP

 


Study suggests multisystem inflammatory syndrome in children (MIS-C) is rare among vaccinated teens.

25 Feb, 2022 | 11:29h | UTC

Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation – The Lancet Child & Adolescent Health

Commentaries:

When vaccine adverse event reporting generates hope, not fear – The Lancet Child & Adolescent Health

MIS-C rare in COVID-vaccinated teens, study finds – CIDRAP

Vaccination Greatly Reduces Odds of MIS-C in Teens Who Get COVID – HealthDay

 

Commentary on Twitter

 


Editorial: Addressing vaccine inequity — Covid-19 vaccines as a global public good.

24 Feb, 2022 | 10:41h | UTC

Addressing Vaccine Inequity — Covid-19 Vaccines as a Global Public Good – New England Journal of Medicine

 


RCT: Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine.

24 Feb, 2022 | 10:20h | UTC

Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial – Annals of Rheumatic Diseases

Commentary: Suspend Methotrexate for RA Patients Getting COVID Vax?— It’s not a simple choice, Brazilian study suggests (free registration required)

 


[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

24 Feb, 2022 | 10:30h | UTC

Fourth dose of COVID vaccine offers only slight boost against Omicron infection – Nature

Original Study: 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC – medRxiv

 


Two large populational-based studies find a slightly increased risk of thrombotic events following AstraZeneca COVID-19 vaccination.

24 Feb, 2022 | 10:23h | UTC

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England – PLOS Medicine

See also: First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales – PLOS Medicine

Commentaries:

Two studies find only small elevated risk of blood clots following AstraZeneca COVID-19 vaccination – PLOS

Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax – TCTMD

 


Meta-analysis finds low risk of a second allergic reaction to SARS-CoV-2 mRNA vaccines in patients with an allergic reaction with the first dose.

22 Feb, 2022 | 10:05h | UTC

Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis – JAMA Internal Medicine

 

Commentary on Twitter

 


Opinion by Dr. Eric Topol | Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed.

22 Feb, 2022 | 10:07h | UTC

Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed – The Guardian

 

Commentary from the author on Twitter (thread – click for more)

 


[Preprint] A large-scale observational study in Chile found CoronaVac (an inactivated SARS-CoV-2 vaccine) was associated with an effectiveness of 74.5% against infection, 91.0% against hospitalization, and 93.8% against ICU admission in children aged 6 to 16 years.

22 Feb, 2022 | 09:58h | UTC

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Children and Adolescents: A Large-Scale Observational Study – Preprints with The Lancet

Commentary: Full schedule of CoronaVac vaccine shown to be highly effective in children – News Medical

 


Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.

21 Feb, 2022 | 09:33h | UTC

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis – International Journal of Infectious Diseases

 


New U.S. childhood and adolescent immunization schedule released by ACIP.

18 Feb, 2022 | 10:05h | UTC

Recommended Childhood and Adolescent Immunization Schedule: United States, 2022 – Pediatrics

See also:

Child and Adolescent Immunization Schedule: Recommendations for Ages 18 Years or Younger, United States, 2022 – Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2022 – CDC Morbidity and Mortality Weekly Report

 


New U.S. adult immunization schedule released by ACIP.

18 Feb, 2022 | 10:07h | UTC

Recommended Adult Immunization Schedule, United States, 2022 – Annals of Internal Medicine

News release: New adult immunization schedule recommends changes to zoster, pneumococcal, and hep B vaccines – American College of Physicians

See also: Adult Immunization Schedule: Recommendations for Ages 19 Years or Older, United States, 2022 – Centers for Disease Control and Prevention

 


Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

17 Feb, 2022 | 10:11h | UTC

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection – New England Journal of Medicine

 


Retrospective cohort study: Pfizer vaccine reduces the risk of reinfection after recovery from Covid-19.

17 Feb, 2022 | 10:13h | UTC

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 – New England Journal of Medicine

 

Commentary on Twitter

 


England to offer Covid jab to five to 11-year-olds.

17 Feb, 2022 | 10:09h | UTC

England to offer Covid jab to five to 11-year-olds – BBC

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.